Current filters:  
Canada
Healthcare
Life Sciences, Biotechnology & Nanotechnology
Canada
Fasken
On January 26, Health Canada issued a notice clarifying how a drug's "dormant" status on the drug product database may affect whether that drug...
Fasken
The federal Parliament tabled Bill C-64, An Act respecting pharmacare (the "Bill"), on February 29, 2024. The Bill outlines the first phase of the federal government's...
Fasken (French)
Le 26 janvier, Santé Canada a publié un avis précisant comment l'état « dormant » d'un médicament dans la base de données sur les produits pharmaceutiques...
Cassels
The Patented Medicine Prices Review Board Canada (PMPRB) published its "What We Learned Report" (Report) on February 15, 2024...
Aird & Berlis LLP
For many Canadians, pharmaceutical names are an alphabet soup. Biogen's BYOOVIZ and Novartis's BEOVU trademarks are classic examples of drug brand names comprised of coined words.
Gowling WLG
Once you decide to file a patent, you must determine what it will cover. Obviously, you need to protect your invention, but to reduce the risk of others designing around your patent in the future...
Smart & Biggar
We previously reported amendments to Part 1.1 of the Medical Devices Regulations that created a permanent regulatory framework for expediting access to COVID-19 medical devices.
Smart & Biggar
On December 23, 2023, the Federal Court of Appeal (FCA) held that it was an abuse of process for Apotex to raise invalidity in defending actions under the Patented Medicines...
Fasken
This bulletin provides an update on the most recent decision of the Federal Court in the ongoing saga concerning Galderma's dermatology medicine...
Gowling WLG
Allergan and Abbvie brought this action under the PM(NOC) Regulations, seeking to prevent the issuance of a Notice of Compliance for Juno Pharmaceuticals' generic version of Allergan's...
Smart & Biggar
In our annual review of developments in Canadian patent law, we considered over 60 patent decisions reported last year.
Fasken
This article provides an update to our series on the use of real-world data ("RWD") and real-world evidence ("RWE"). The Pharmaceutical Advertising Advisory Board (PAAB) has published revisions...
Torys LLP
It means three things to me. First, it means exactly what you said. It's sustainable. It means it's a continuous and meaningful flow of ideas...
Smart & Biggar
Eli Lilly v Teva, Pharmascience, Riva, Apotex, Mylan (tadalafil, CIALIS) – Following a summary trial, Lilly's infringement actions were dismissed: composition claims directed to "a physiologically acceptable salt"...
BCF Business Law
Pharmaceutical and medical products are no exception to the fierce competition between companies to make their products stand out.
Smart & Biggar
Below are Rx IP Update's most-read articles of 2023 (see also our 2023 Highlights in Canadian Life Sciences IP and Regulatory Law)...
Worldwide
Bennett Jones LLP
The Canadian Venture Capital Association (CVCA) released its annual look at the state of venture capital (VC) funding in Canada in their 2023 Market Overview.
Fasken
On January 5, 2024, the U.S. Food and Drug Administration (FDA) signed off on Florida's request to import prescription drugs from Canada under the Section 804 State Importation Program (SIP).
Smart & Biggar
A proposed program by the state of Florida to import certain prescription drugs from Canada has received the approval of the United States Food and Drug Administration (FDA): FDA news release on January 5, 2024.
Bereskin & Parr LLP
Once again, 2023 saw much action in Canadian life sciences patent news. Here we provide a summary of some of the key updates and decisions that you should know.
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Popular Contributors
Upcoming Events
Mondaq Social Media